Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a range of high-quality anti-IL2 recombinant antibody products to serve global customers in IL2-related basic research and therapeutic development. Our antibodies are carefully designed to precisely target IL2 and exhibit high sensitivity. Each of these antibodies undergoes rigorous quality control to ensure exceptional performance in customers' significant projects.
IL-2 is a multifaceted cytokine with diverse effects on immune cells, ranging from promoting T cell proliferation and differentiation to influencing regulatory T cell function. Its pleiotropic nature, including both autocrine and paracrine actions, highlights the complexity of its biological roles. While IL-2's ability to stimulate cytotoxic effector cells has shown promise in cancer immunotherapy, its systemic administration often leads to significant side effects. Therefore, strategies aimed at targeting IL-2 signaling more precisely, such as through engineered IL-2 variants or cell-based delivery systems, are actively being explored to improve its therapeutic efficacy and minimize adverse events.
IL-2; interleukin 2; TCGF; lymphokine.
The protein encoded by this gene is a secreted cytokine that is important for the proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). The expression of this gene in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling the precise expression of a single gene. The targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role of this gene in the immune response to antigenic stimuli.
Creative Biolabs offers a diverse collection of recombinant anti-IL2 antibodies meticulously engineered to exhibit high specificity and affinity. Our portfolio encompasses a range of antibody formats, including monoclonal antibodies, polyclonal antibodies, and antibody fragments, each tailored to specific research needs. These antibodies demonstrate exceptional performance across various applications, such as immunoprecipitation, WB, ELISA, flow cytometry, and immunohistochemistry. Leveraging our robust platform, we provide researchers and developers with cutting-edge tools to propel advancements in immunology, cancer biology, and related fields, facilitating the development of novel therapeutics targeting IL-2 signaling pathways.
Table 1. Featured anti-IL2 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
PABL-609 | Mouse Anti-Il2 Recombinant Antibody (clone JES6-1) | Mouse | Mouse IgG | FC, FuncS, IHC, ELISA |
PABC-506 | Human Anti-IL2 Recombinant Antibody (PABC-506) | Human | Human IgG1, λ | Inhib, ELISA, FC, FuncS |
ZG-0499J | Mouse Anti-IL2 Recombinant Antibody (ZG-0499J) | Human | Mouse IgG | WB, ELISA |
HPAB-M0116-YC | Mouse Anti-IL2 Recombinant Antibody (clone MAB602) | Human, Mouse | Mouse IgG | ELISA, FC |
HPAB-0112-YC | Human Anti-IL2 Recombinant Antibody (HPAB-0112-YC) | Human | Human IgG1 | WB, ELISA, FC, IHC |
Creative Biolabs offers a wide range of high-quality anti-IL2 recombinant antibodies that are meticulously developed with pinpoint accuracy, ensuring superior specificity and strong binding affinity. Our rigorous quality control and comprehensive validation data (such as binding kinetics and specificity analysis) provide researchers with the confidence to use these antibodies in a variety of research situations.
Fig.1 ELISA analysis of anti-IL2 antibody
(Cat# PABC-506, Creative Biolabs).
Fig.2 WB analysis of anti-IL2 antibody
(Cat# PABC-506, Creative Biolabs).
Fig.3 DB analysis of anti-IL2 antibody
(Cat# PABC-506, Creative Biolabs).
Fig.4 WB analysis of anti-IL2 antibody
(Cat# ZG-0499J, Creative Biolabs).
Fig.5 ELISA analysis of anti-IL2 antibody
(Cat# PABL-609, Creative Biolabs).
Fig.6 WB analysis of anti-IL2 antibody
(Cat# PABL-609, Creative Biolabs).
Creative Biolabs consistently delivers high-quality anti-IL2 antibodies produced using advanced genetic engineering techniques.
Featured Anti-IL2 Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-IL2 recombinant antibody production.
Fig.8 Gram-scale anti-IL2 recombinant antibody production.
Creative Biolabs offers a diverse portfolio of high-quality anti-IL2 recombinant antibodies in various formats to cater to the diverse research needs of scientists worldwide.
Fig.9 Full-length anti-IL2 recombinant antibody production and modalities.
Table 2. Public drug targeting IL2.
Company | Research Phase | Classification | Condition |
Ajinomoto Alfa Wassermann Citius Pharmaceuticals Dr Reddy's Laboratories Eisai Ferrer Friedrich-Alexander-Universitaet (Originator) Ligand (Originator) Lilly MD Anderson Cancer Center National Cancer Institute Perrigo Seragen (Ligand) TSD Japan |
Launched - 1999 |
Cancer Immunotherapy Fusion Proteins IL-2 Polypeptides, from 41 AA |
Autoimmune disease Cancer Cancer, breast Cancer, lung (non-small cell) (NSCLC) Cancer, ovary (epithelial) Cancer, pancreas, metastatic Cancer, solid tumor Chronic lymphocytic leukemia Cutaneous T-cell lymphoma Graft-versus-host disease Leukemia-lymphoma, adult T-cell Lymphoma Lymphoma, diffuse large B-cell Lymphoma, T-cell Melanoma, metastatic Non-Hodgkin lymphoma Peripheral T-cell lymphoma Psoriasis |
Takeda (Originator) | Launched - 1992 |
Cancer Immunotherapy IL-2 Polypeptides, from 41 AA Recombinant proteins |
Angiosarcoma |
Biogen (Originator) Roche (Originator) Shionogi |
Launched - 1992 |
Cancer Immunotherapy IL-2 Polypeptides, from 41 AA Recombinant proteins |
Angiosarcoma Cancer, colorectal, metastatic |
Children's Hospital of Philadelphia Chiron (Novartis Vaccines and Diagnostics) Clinigen Hospital Universitario Puerta de Hierro (HUPH) M.D. Anderson Cancer Center (MD Anderson Cancer Center) National Cancer Institute National Cancer Institute (NCI) (National Cancer Institute) National Cancer Institute (US) (National Cancer Institute) National Institute Allergy Infect Dis Novartis (Originator) Novartis Vaccines and Diagnostics (Originator) Prometheus (Prometheus Biosciences) University of Alabama at Birmingham University of Pittsburgh |
Launched - 1989 |
Cancer Immunotherapy IL-2 Polypeptides, from 41 AA Recombinant proteins |
Acute coronary syndrome Acute myeloid leukemia Amyotrophic lateral sclerosis Cancer, breast Cancer, breast, metastatic Cancer, kidney Cancer, kidney, metastatic Cancer, kidney (renal cell carcinoma) Cancer, lung, metastatic Cancer, lung (non-small cell) (NSCLC) Cancer, metastatic (to lung) Cancer, mouth Cancer, ovary Chronic myeloid leukemia Cutaneous T-cell lymphoma Diabetes type 1 Gastroesophageal reflux disease (GERD) Graft-versus-host disease Infection, HIV Melanoma, intraocular Melanoma, metastatic Myelodysplasia Myeloid leukemia Neuroblastoma Non-Hodgkin lymphoma Transplant rejection Wiskott-Aldrich syndrome |
Biotech Ltd. (Originator) | Launched |
Cancer Immunotherapy IL-2 Polypeptides, from 41 AA Recombinant proteins |
Cancer Immunological Disorders Infections |
Philogen (Originator) Sun Pharma |
Phase III |
Cancer Immunotherapy Fusion Proteins IL-2 Immunocytokines Polypeptides, from 41 AA Single-Chain V-Domain Antibody Fragment (scFv) Tumor Necrosis Factor-alpha (TNF-alpha) |
Cancer, skin Cancer, skin (basal cell carcinoma) Cancer, skin (squamous cell carcinoma) Carcinoma, Merkel cell Cutaneous T-cell lymphoma Kaposi sarcoma Melanoma |
Peking University People's Hospital | Phase III |
IL-2 Polypeptides, from 41 AA Recombinant proteins |
Behcet's disease Dermatomyositis Graft-versus-host disease Inflammatory myopathy Macrophage activation syndrome Rheumatoid arthritis Sjogren syndrome Systemic lupus erythematosus |
Innovent Biologics (Originator) | Phase II |
Cancer Immunotherapy Fusion Proteins IL-2 Immunocytokines Monoclonal Antibodies Polypeptides, from 41 AA |
Cancer Cancer, solid tumor Lymphoma Melanoma |
Second Xiangya Hosp Central South Univ (Originator) | Phase II |
IL-2 Polypeptides, from 41 AA Recombinant proteins |
Pemphigus vulgaris Urticaria |
Merck & Co (Originator) Merck & Co. (Merck & Co) Pandion Therapeutics (Merck & Co) |
Phase II |
Fc Fusion Proteins IL-2 Polypeptides, from 41 AA |
Atopic dermatitis Autoimmune disease Rheumatoid arthritis Systemic lupus erythematosus Ulcerative colitis Vitiligo, non-segmental |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
As a senior leader in antibodies, Creative Biolabs possesses solid theoretical and production expertise and has successfully established an efficient antibody manufacturing process to ensure that high-quality anti-IL2 recombinant antibodies are generated within the customer's preferred time frame. If you are interested in our anti-IL2 recombinant antibodies, please contact us for a consultation.